Evidence map›Paper›PMID 37155488›Full record

ArticleJournal of functional foods2023

Chewable tablet with herbal extracts and propolis arrests Wuhan and Omicron variants of SARS-CoV-2 virus.

Öznur Karaoğlu, Müge Serhatlı, Ebru Pelvan, Bülent Karadeniz, Ilknur Demirtas, Gamze Çakırca, Hande Sipahix, Yağmur Özhan, Gözdem Karapınar, Mohammad Charehsaz and 3 more

Abstract read
In one paragraph

Article in Journal of functional foods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Öznur KaraoğluLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Müge SerhatlıLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Ebru PelvanLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Bülent KaradenizLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Ilknur DemirtasLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Gamze ÇakırcaLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.
Hande SipahixDepartment of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Yağmur ÖzhanDepartment of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Gözdem KarapınarDepartment of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Mohammad CharehsazDepartment of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Ahmet AydınDepartment of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Erdem YesiladaDepartment of Pharmacognosy, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey.
Cesarettin AlasalvarLife Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevention of COVID-19 is of paramount importance for public health. Some natural extracts might have the potential to suppress COVID-19 infection. Therefore, this study aimed to design a standardised, efficient, and safe chewable tablet formulation (with propolis and three herbal extracts) for possible prevention against two variants (Wuhan B.1.36 and Omicron BA.1.1) of SARS-CoV-2 virus and other viral infections. Green tea, bilberry, dried pomegranate peel, and propolis extracts were selected for this purpose. Cytotoxicity and antiviral activity of each component, as well as the developed chewable tablet, were examined against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus using Vero E6 cells with the xCELLigence real-time cell analyser-multiple plates system. Anti-inflammatory and analgesic activities, as well as mutagenicity and anti-mutagenicity of the chewable tablet were also analysed. Compared to the control, it was observed that the chewable tablet at concentrations of 110 and 55 µg/mL had antiviral activity rates of 101% and 81%, respectively, for the Wuhan variant and 112% and 35%, respectively, for the Omicron variant. The combination of herbal extracts with propolis extract were synergically more effective (∼7-fold higher) than that of individual extract. The present work suggests that a combination of herbal extracts with propolis at suitable concentrations can effectively be used as a food supplement for the prevention of both variants of the SARS-CoV-2 virus in the oral cavity (the first entry point of the SARS-CoV-2 virus).

Indexed as

AntiviralChewable tabletCOVID-19CytotoxicityExtractsPhenolicsPropolis

Identifiers

PMID37155488
PMCPMC10113600

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.